Developers from the CIGB made the announcement on Friday.
Havana, July 16 (RHC) 'Cuba's Abdala vaccine showed 100 percent efficacy in Phase III clinical trials to prevent severe systemic disease and death from Covid-19, its developers announced Friday.
This immunizer, the first in Latin America and developed by the island's Center for Genetic Engineering and Biotechnology (CIGB), had already shown 92.28 percent efficacy against the symptomatic disease.
The clinical efficacy data from Abdala's Phase III trial are already available, with excellent results, and it is currently being scaled up to an effectiveness study with more than 300,000 people.
